Vivian Eisfeller

Daiichi Sankyo Co., Ltd. is a global pharmaceutical company that develops and markets innovative pharmaceutical products in over 20 countries worldwide. It focuses on the research and development of novel drugs and treatments for cardiovascular, metabolic, immune, and infectious diseases, as well as cancer.

Daiichi Sankyo Company, Limited

daiichi_sankyo_company_limited

Free Corporate Rating

• SB2A Temperature Range: 1.5°C < SB2A ≤ 2°C
• Description: These companies, while not in the top tier of priority enablers, still play a crucial role in advancing climate goals. Their activities align within the 1.5 to 2-degree temperature range, signifying a substantial contribution to mitigating climate change.

● SB2A temperature range: 3°C ≤ SB2A < 4°C
● Description: Engaging companies face a critical need for environmental improvement as their carbon intensity is increasing. With SB2A indicating a substantial temperature misalignment (3°C ≤ SB2A < 4°C), these companies are recognized as having a high environmental impact. Engaging companies are urged to prioritize and accelerate their sustainability initiatives to address their significant climate-related challenges.

• SB2A Temperature Range: SB2A ≤ 1.5°C
• Description: Companies falling into this category demonstrate an exceptional commitment to climate alignment. Their activities contribute significantly to maintaining global warming well below the 2-degree target, positioning them as leaders in enabling a sustainable future.

● SB2A temperature range: ≥ 4°C
● Description: Priority Engaging companies face a critical need for environmental improvement. With SB2A indicating a substantial temperature misalignment (≥ 4°C), these companies are recognized as having a very high environmental impact. Priority Engaging companies are urged to prioritize and accelerate their sustainability initiatives to address their significant climate-related challenges.

• SB2A Temperature Range: 2°C ≤ SB2A < 3°C
• Description: Companies in this category are strategically positioning themselves for a sustainable transition. Their commitment is evident through an decrease in carbon intensity at company level together with certified targeted plan for further reduction and a decrease in temperature.

• SB2A Temperature Range: 2°C ≤ SB2A < 3°C
• Description: Transitioning companies are actively engaged in reducing their carbon footprint. The decrease in the carbon intensity at company level is the sign that these entities are making strides toward sustainability, even if a specific reduction target is yet to be formalized.

Rating peers in sector of {{sector}} (based on {{total}} companies)

Discover other companies in {{sector}} with {{score}} score

Climate Rating: Priority Transitioning - Daiichi Sankyo Co., Ltd. is a global pharmaceutical company that develops and markets innovative pharmaceutical products in over 20 countries worldwide. It focuses on the research and development of novel drugs and treatments for cardiovascular, metabolic, immune, and infectious diseases, as well as cancer.

Free Corporate Rating

Daiichi Sankyo Company, Limited

ISIN

LEI

Description

Rating peers in sector of Health Care (based on 265 companies)

9%

Leader

9%

Aligned

5%

Actively
transitioning

27%

Transitioning

40%

Not
aligned

10%

Laggard

Discover other companies in Health Care with Actively transitioning score

Get in touch!

Free Corporate Rating

Daiichi Sankyo Company, Limited

ISIN

LEI

Description

Rating peers in sector of Health Care (based on 265 companies)

9%

Leader

9%

Aligned

5%

Activelytransitioning

27%

Transitioning

40%

Notaligned

10%

Laggard

Discover other companies in Health Care with Actively transitioning score

Get in touch!

Actively
transitioning

Not
aligned